Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q1 2025 Pharma Commercialization Market Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Published April 2025

We just released our latest update on the pharmaceutical commercialization landscape. The pharmaceutical industry is racing to offset a looming patent cliff, with >$350B in annual sales at risk by 2030, and outsourced commercialization partners are playing a critical role in that strategy. If you are a founder, executive, or investor in the space, we hope you find this report helpful as you plan for the year ahead.

Key takeaways from Q1:

  • Surge in platform creation and add-on M&A activity
  • Secondary buyouts gaining steam as larger sponsors consolidate the consolidators
  • Continued push toward full-service models with expanded regulatory, HEOR, and market access capabilities
  • Growing role of AI, digital analytics, and patient-centric strategies
  • Deepening focus on rare disease, cell & gene, and other high-growth therapeutic areas

Please see the following link to a copy of the blinded report. If you would like access to a full copy of the update, please email us at pharmacommercialization@providenthp.com.

[holo_button icon=”/wp-content/uploads/2025/04/PHP-Pharma-Commercialization-Quarterly-Update-Q1-2025-vF-Blinded-1.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]